Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Law and the Biosciences"
DOI: 10.1093/jlb/lsac001
Abstract: Abstract Neovascular age-related macular degeneration (AMD) is a progressive eye disease and is a leading cause of vision loss in the Western world. Vascular endothelial growth factor inhibitors have become a mainstay of treatment for… read more here.
Keywords: competition law; competition; biologic drugs; case ... See more keywords